Exclusive Online Content
Univercells Acquires SynHelix, Entering Into Synthetic Biology & the Race to Next-Generation DNA Synthesis
Univercells S.A. (Univercells) recently announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable, and….
Sosei Heptares & Verily to Collaborate to Generate Novel Drug Candidates Against GPCR Targets for Immune-Mediated Diseases
Sosei Group Corporation and Verily recently announced they have entered into a strategic research collaboration. The research agreement brings together the….
AVITA Medical Establishes Proof-of-Concept for Novel Treatments Using Genetically Modified Skin Cells
AVITA Medical, Inc. recently announced that preclinical data successfully established proof-of-concept in two key areas of cell-based gene therapy – skin rejuvenation and….
Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines From AstraZeneca
Covis Pharma Group recently announced Covis Pharma GmbH has completed the acquisition of Eklira (aclidinium bromide), known as Tudorza in the US and marketed as Bretaris in some countries, and….
MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases
MannKind Corporation recently announced that has extended its collaboration with Thirona Bio, Inc. with the purchase of a second convertible note issued by Thirona, and the appointment of….
Pfizer & BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
Pfizer Inc. and BioNTech SE recently announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles….
Rain Therapeutics & Roche to Collaborate on Clinical Trial of Milademetan Combination With Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications
Rain Therapeutics Inc. recently announced a clinical supply agreement with Roche for the supply of the anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody, atezolizumab…..
Cue Biopharma & LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102
Cue Biopharma, Inc. and LG Chem Life Sciences recently announced a key milestone in the selection of a clinical product candidate has been reached in their collaboration for CUE-102, an Immuno-STAT biologic, jointly developed to….
Curia Unveils Comprehensive mRNA Solution
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, recently unveiled its messenger RNA (mRNA) solution, which includes discovery, process development and mRNA drug substance production, through….
Santhera Enters Exclusive License Agreement With Sperogenix for Vamorolone in Rare Diseases in the Greater China Region
Santhera Pharmaceuticals recently announced it has entered into an exclusive license agreement with Sperogenix Therapeutics, a China-based company specializing in orphan diseases. Under this agreement….
EXCLUSIVE ONLINE CONTENT
PlaqueTec & the Babraham Institute Collaborate on Early Phase Target Discovery & Development
Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec….
Biopharmaceutical Mega M&A Deals Surge by 71% YoY During Q1 2024
Mergers and acquisitions (M&As) in the biopharmaceutical industry have rebounded with a $76.9 billion increase in total deal value seen from 2022 to 2023. In Q1 2024 alone, biopharmaceutical M&A reached a total deal value of….
ElevateBio Announces New US Patents for Lead Life Edit CRISPR Systems & Adenine Deaminases Enabling Advanced Gene Editing Techniques
ElevateBio is building a robust portfolio of patents protecting its novel technologies while the Company scales as the world’s first integrated genetic medicine foundry….
AbbVie & Gilgamesh Pharmaceuticals Announce Collaboration & Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
Collaboration to leverage AbbVie’s psychiatry expertise and Gilgamesh’s innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders….
AC Immune & Takeda Sign Exclusive Option & License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression….